[Special Stock] Hwail Yakpum Rises on Dexmethasone Raw Material Production Amid COVID-19 Resurgence
[Asia Economy Reporter Hyunseok Yoo] Hwail Pharm is showing strong performance. As the number of new domestic COVID-19 cases increases, the production of the raw material for 'Dexamethasone,' used as a treatment for COVID-19, has gained attention.
As of 9:50 AM on the 16th, Hwail Pharm was trading at 13,650 KRW, up 4.20% (550 KRW) compared to the previous trading day.
Domestic quarantine authorities prescribe Dexamethasone or Remdesivir to severe COVID-19 patients. Dexamethasone suppresses excessive immune and inflammatory responses such as cytokine storms, protecting organs like the lungs.
Additionally, Hwail Pharm is known to supply 'Entecavir,' the raw material for hepatitis B treatment.
Recently, domestic pharmaceutical companies have been developing treatments for COVID-19 by 'repurposing' drugs for pancreatitis and hepatitis B.
Hot Picks Today
If You’re Worried About Market Swings: "Steady Cash Flow Even Amid Volatility" - Experts Recommend These ETFs
- No Bacteria Detected in Arisu After 24 Hours of Repeated Drinking from a Tumbler
- "We Can't Just Let Them Be Damaged Inside"... Samsung Electronics Removes 360,000 Wafers in Preparation for Strike
- Wife in $6.7 Million Debt Took Out $3 Million in Husband's Life Insurance, Poisoned Him... US Court: "She Can Never Be Released"
- "He's Handsome, It's Such a Pity?"... Lawyer Responds to Bizarre 'Appearance Evaluation' of High School Girl Murder Suspect
Meanwhile, according to the Central Disease Control Headquarters, as of midnight today, the number of new domestic COVID-19 cases was 848, with a cumulative total of 44,364 cases.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
